All In Biotech

Drug Trial Radar · NCT01687712

Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF

Phase III Investigator and Assessor Blinded 1:1 Randomized, Parallel-group Multicenter Study to Compare Efficacy and Safety of Two r-hFSH Formulations (AFOLIA vs Gonal-f® RFF) in Normal Ovulatory Women 35 to 42 Years Old Undergoing in Vitro Fertilization

Last checked: Nov 20, 2026Latest source record: Dec 5, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,100 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,100

Actual

Start

Nov 25, 2013

Primary completion

Sep 10, 2015

Study completion Nov 14, 2016

Sponsor

Lead sponsor
Fertility Biotech AGIndustry
Sponsor type
Industry
First posted
Sep 19, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 35 years, up to 42 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to show that AFOLIA, a recombinant manufactured human follicle stimulating hormone (r-hFSH) has a similar efficacy and safety profile compared to Gonal-f® RFF.

Conditions

  • Infertility

Interventions

  • AFOLIADrug

    225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached

  • Gonal-f® RFFDrug

    225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Pregnancy Rate After One Cycle of Treatment - ITT PopulationTime frame: Six weeks post embryo transfer
  2. Clinical Pregnancy Rate After One Cycle of Treatment - PP PopulationTime frame: Six weeks post embryo transfer

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Physicians Research Group

    Tempe, Arizona

  • HRC Fertility

    Encino, California

  • Reproductive Associates of Delaware

    Newark, Delaware

  • FL Fertility Institution

    Tampa, Florida

  • Georgia Reproductive Specialists

    Atlanta, Georgia

  • Fertility Centers of Illinois

    Chicago, Illinois

  • In Via Fertility Specialists

    Hoffman Estate, Illinois

  • Shady Grove Fertility RSC

    Rockville, Maryland

  • Nevada Center for Reproductive Medicine

    Reno, Nevada

  • Cooper Institute of Reproductive Hormonal Disorders, P.C.

    Marlton, New Jersey

  • Institute for Reproductive Health

    Cincinnati, Ohio

  • Abington Reproductive Medicine

    Abington, Pennsylvania

  • Main Line Fertility Center

    Bryn Mawr, Pennsylvania

  • Shady Grove Fertility RSC, Chesterbrook, PA

    Chesterbrook, Pennsylvania

  • University of Penn

    Philadelphia, Pennsylvania

  • Fertility Associates of Memphis

    Memphis, Tennessee

  • Texas Fertility Center

    Austin, Texas

  • Center for Assisted Reproduction

    Bedford, Texas

  • Fertility Specialists of Houston

    Houston, Texas

  • Houston Fertility Institute

    Houston, Texas

  • Center of Reproducitve Medicine

    Webster, Texas

  • Jones Institute for Reproductive Medicine

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.